Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
New York, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight Advancements in gene therapy is a...
-
US & Canada, Nov. 18, 2024 (GLOBE NEWSWIRE) -- According to a new comprehensive report from Global Microbiology CRO Services Market is observing significant growth owing rising practice of...
-
Austin, Nov. 15, 2024 (GLOBE NEWSWIRE) -- The S&S Insider report indicates that, “Pharmaceutical Sterility Testing Market was valued at USD 1.42 Billion in 2023 and is projected to reach USD...
-
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative...
-
- EMA erteilt Freigabe zur Weiterentwicklung von Belrestotug 400 mg + Dostarlimab als empfohlene Phase-III-Dosis und Aktivierung der klinischen Prüfzentren für GALAXIES Lung-301 in der EU-...
-
- Autorisation de l’AEM en faveur de l’étude associant du belrestotug 400 mg + dostarlimab comme dose recommandée de Phase III et l’activation des sites cliniques GALAXIES Lung-301 dans l’UE- Données...
-
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 ...
-
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in...
-
Austin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Market Size & Growth Insights: According to the S&S Insider, “The Rugged Electronics Market Size was valued at USD 14.01 Billion in 2023 and is...
-
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of...